This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Prometheus Biosciences Croissance future
Future contrôle des critères 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Prometheus Biosciences.
Informations clés
12.1%
Taux de croissance des bénéfices
14.9%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 28.7% |
| Taux de croissance des recettes | 70.2% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 13 Jun 2023 |
Mises à jour récentes de la croissance future
Recent updates
We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth
May 17
Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation
Dec 03We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully
Aug 19Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M
Aug 11We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely
May 04Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases
Dec 08Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans
Nov 16Prometheus Biosciences: Precision Medicine For IBD
Sep 22Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2025 | 89 | -293 | -194 | -446 | 9 |
| 12/31/2024 | 7 | -232 | -173 | -302 | 10 |
| 12/31/2023 | 3 | -193 | N/A | -208 | 6 |
| 3/31/2023 | 4 | -151 | -136 | -133 | N/A |
| 12/31/2022 | 7 | -142 | -126 | -123 | N/A |
| 9/30/2022 | 7 | -133 | -107 | -104 | N/A |
| 6/30/2022 | 7 | -123 | -100 | -97 | N/A |
| 3/31/2022 | 6 | -108 | -76 | -74 | N/A |
| 12/31/2021 | 3 | -90 | -65 | -64 | N/A |
| 9/30/2021 | 3 | -69 | -48 | -47 | N/A |
| 6/30/2021 | 2 | -50 | -35 | -34 | N/A |
| 3/31/2021 | 2 | -38 | -42 | -42 | N/A |
| 12/31/2020 | 1 | -31 | -28 | -28 | N/A |
| 12/31/2019 | 1 | -17 | -20 | -20 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: RXDX is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: RXDX is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: RXDX is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: RXDX's revenue (70.2% per year) is forecast to grow faster than the US market (7.4% per year).
Croissance élevée des revenus: RXDX's revenue (70.2% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if RXDX's Return on Equity is forecast to be high in 3 years time